Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03242460
Other study ID # PORYOU
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 12, 2015
Est. completion date May 2, 2019

Study information

Verified date February 2020
Source Kosin University Gospel Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In Korea, VMP is most commonly used as frontline treatment in patients with newly diagnosed MM who were ineligible for high-dose therapy. Recently National Insurance began to reimburse the second-line LD when the bortezomib-containing treatment failed to salvage the patients. Patients who have relapsed MM after exposure to the above agents and have progressive disease have a short life expectancy. Third-line therapy is needed for retrieving the patients hereafter. And substantial proportion of patients will attain an advanced age. To examine if time to disease progression is maintained and tolerability is improved with lower dexamethasone dose, the dose of dexamethasone is reduced when at least a minimal response is achieved after 3 months of treatment with the initial dose. Three months later (6 months after the initial treatment), the response remains in stable disease, 2nd dose reduction (dexamethasone 10mg or prednisone 50mg) will be carried out.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date May 2, 2019
Est. primary completion date April 24, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients must have evaluable multiple myeloma with at least one of the following (within 21 days of starting treatment)

- Serum M-protein = 0.5g/dL, or

- In subjects without detectable serum M-protein, Urine M-protein = 200mg/24 hour, or serum free light chai (sFLC) > 100mg/L (involved light chain) and an abnormal kappa/Lambda ratio

- Patients were ineligible for autologous stem cell transplantation

- Must be relapse refractory to initial therapy with bortezomib, melphalan and prednison and then lenalidomide plus dexamethasone.

- Refractoriness is defined as disease progression on treatment or progression within 6 months after the last dose of a given therapy. Relapse is defined according to the criteria of IMWG

- Males and females = 18 years of age or > country's legal age for adult consent

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2

- Patients must meet the following clinical laboratory criteria with 21 days of starting treatment:

- Absolute neutrophil count (ANC) = 1,000/mm3 and platelet = 50,000/mm3 (= 30,000/mm3 if myeloma involvement in the bone marrow is >50%)

- Total bilirubin = 1.5 x the upper limit of the normal range (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3 x ULN.

- Calculated creatinine clearance = 30mL/min or creatinine < 3mg/dL.

- Written informed consent in accordance with federal, local and institutional guidelines

Exclusion Criteria:

- Female patients who are lactating or pregnant

- Multiple Myeloma of IgM subtype

- Glucocorticoid therapy (prednisolone > 30mg/day or equivalent) within 14 days prior to informed consent obtained

- POEMS syndrome, plasma cell leukemia or circulating plasma cells = 2 x 109/L, Waldenstrom's Macroglobulinaemia, or Patients with known amyloidosis

- Peripheral neuropathy grade > 2

- Chemotherapy with approved or investigation anticancer therapeutics within 21 days prior to starting pomalidomide treatment

- Focal radiation therapy within 7 days prior to start of pomalidomide. Radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to start of pomalidomide

- Immunotherapy (excluding steroids) 21 days prior to start of pomalidomide

- Major surgery (excluding kyphoplasty) within 28 days prior to start of pomalidomide

- Active congestive heart failure (New York Heart Association [NYHA] Class III or IV), symptomatic ischaemia, or conduction abnormalities uncontrolled by conventional intervention. Myocardial infarction within 4 months prior to informed consent obtained

- Known HIV seropositive, hepatitis C infection, and/or hepatitis B (except for patients with hepatitis B surface antigen or core antibody receiving and responding to antiviral therapy directed at hepatitis B: these patients are allowed)

- Second malignancy within the past 3 years except:

- Adequately treated basal cell or squamous cell skin cancer

- Carcinoma in situ of the cervix

- Breast carcinoma in situ with full surgical resection

- Patients with steroid or lenalidomide hypersensitivity

- Patients with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to starting pomalidomide treatment

- Any clinically significant medical disease or psychiatric condition that, in the investigator's opinion, may interfere with protocol adherence or a patient's ability to give informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pomalidomide 4 MG
Pomalidomide 4mg Days 1-21
Dexamethasone 20mg
Dexamethasone 20mg Days 1, 8, 15, 22
Cyclophosphamide 400mg
Cyclophosphamide 400mg Days 1, 8, 15

Locations

Country Name City State
Korea, Republic of Catholic university of korea, Seoul ST. Mary's Hospital. Seoul

Sponsors (1)

Lead Sponsor Collaborator
Kosin University Gospel Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Median Progression-free Survival (PFS) Kaplan-Meier method 2 years follow up
Secondary Objective Response Rate (ORR) International Myeloma Working Group,( IMWG) 2 years follow up
Secondary Overall survival (OS) Kaplan-Meier method 2 years follow up
Secondary Safety evaluations assessed using Common Terminology Criteria for Adverse Events v4.0 Common Terminology Criteria for Adverse Events v4.0 2 years follow up
See also
  Status Clinical Trial Phase
Recruiting NCT03140943 - Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Phase 2
Recruiting NCT05066022 - A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma N/A
Recruiting NCT06182696 - OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM Phase 1/Phase 2
Recruiting NCT03715478 - Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex Phase 1/Phase 2
Completed NCT02917941 - A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma Phase 2
Not yet recruiting NCT03903406 - Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study
Terminated NCT03836053 - Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma Phase 1
Recruiting NCT05719701 - Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma Phase 1/Phase 2
Recruiting NCT05297240 - Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.
Terminated NCT04272775 - A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) Phase 1
Not yet recruiting NCT06351644 - ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Phase 1/Phase 2
Withdrawn NCT04392648 - A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Phase 1
Active, not recruiting NCT01632150 - Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Phase 2
Completed NCT02831686 - A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma Phase 1
Recruiting NCT06153251 - A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma Phase 1
Completed NCT00882063 - Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma Phase 1/Phase 2
Terminated NCT04017130 - A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT03416374 - A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Phase 4
Recruiting NCT05486975 - This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma. Early Phase 1
Completed NCT03170882 - A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma Phase 2